Responding to declining artemether lumefantrine efficacy in African malaria programs

Recent U.S. CDC guidance extended artemether–lumefantrine (AL) treatment for uncomplicated malaria from 3 to 5 days, raising questions about its relevance to African programs. This recommendation, developed for U.S. clinical practice, does not by itself justify changing African national guidelines. Although artemisinin partial resistance and reduced AL efficacy have been reported at selected African sites, these findings do not establish that standard AL is ineffective across the continent. African trials comparing 3- and 5-day regimens have reported greater lumefantrine exposure with extended treatment, but increased exposure alone does not demonstrate better cure rates, reduced recrudescence or feasibility in routine care. This perspective argues for geographically targeted evaluation rather than blanket adoption. Such studies should integrate therapeutic efficacy outcomes with molecular resistance surveillance, pharmacokinetic data, medicine-quality verification, and assessments of adherence and implementation. Comparative studies should establish whether extended AL offers meaningful clinical advantages over standard AL or alternative effective ACTs before treatment-policy changes are considered.

Authors

Institutions

Publication Details

Journal
Discover Public Health
Published
2026-11-18
DOI
https://doi.org/10.1186/s12982-026-03259-1
Primary Topic
Malaria Research and Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Responding to declining artemether lumefantrine efficacy in African malaria programs

Faith Adedayo Adejumo, Ayomide Raphael Ijabadeniyi
Discover Public Health
Malaria Research and Control
article

Responding to declining artemether lumefantrine efficacy in African malaria programs

Faith Adedayo Adejumo, Ayomide Raphael Ijabadeniyi
article en

Abstract

Recent U.S. CDC guidance extended artemether–lumefantrine (AL) treatment for uncomplicated malaria from 3 to 5 days, raising questions about its relevance to African programs. This recommendation, developed for U.S. clinical practice, does not by itself justify changing African national guidelines. Although artemisinin partial resistance and reduced AL efficacy have been reported at selected African sites, these findings do not establish that standard AL is ineffective across the continent. African trials comparing 3- and 5-day regimens have reported greater lumefantrine exposure with extended treatment, but increased exposure alone does not demonstrate better cure rates, reduced recrudescence or feasibility in routine care. This perspective argues for geographically targeted evaluation rather than blanket adoption. Such studies should integrate therapeutic efficacy outcomes with molecular resistance surveillance, pharmacokinetic data, medicine-quality verification, and assessments of adherence and implementation. Comparative studies should establish whether extended AL offers meaningful clinical advantages over standard AL or alternative effective ACTs before treatment-policy changes are considered.

Discover Public HealthVol. 23(1)
Bowen University (NG)
Good health and well-being
Malaria Research and Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon